Brenner, C., Galluzzi, L., Kepp, O
For observational studies (cohort and case-control), the NewcastleOttawa Scale (NOS) ( Risk of bias was interpreted as follows: i) Low risk: All criteria met or no more than one rated as unclear
Good candidates Researchers studying anti-aging interventions Those investigating wound healing acceleration Researchers exploring hair and skin improvements Those combining with other peptides in tissue repair stacks Researchers with experience handling injectable compounds Poor candidates Individuals with Wilson's disease or copper metabolism disorders Those with active cancer or history of hormone-sensitive cancers (until more research exists) Pregnant or breastfeeding individuals Those taking anticoagulant medications (potential interaction concerns) Individuals with known copper allergies or sensitivities Anyone uncomfortable with self-injection or unable to maintain sterile technique When uncertain, consult a healthcare provider familiar with peptide research before beginning any protocol
When it comes to handling peptides such as Epithalon, researchers need to have several items on hand, including sterile vials, insulin syringes, and bacteriostatic water
See the DermaVue Kottayam clinic page for the full list of treatments and directions
Most people notice a difference after consistent use for eight to twelve weeks
